COMPASS Pathways PLC (CMPS)
| Market Cap | 1.75B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 12.83M |
| EPS (ttm) | -4.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $48.32 |
| Previous Close | $44.93 |
| Change ($) | 3.39 |
| Change (%) | 7.55% |
| Day's Open | 44.66 |
| Day's Range | 44.40 - 49.12 |
| Day's Volume | 287,047 |
| 52-Week Range | 28.83 - 59.20 |
Psychedelic stocks could have another “far out” year ahead with U.S. FDA support, as well as more clinical trials that are under way. The post 5 Groovy Psychedelic Stocks to Buy appeared first...
COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care
COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care
London, UK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental ...
Psilocybin Will Change Mental Health, Compass Pathways Could Be At The Forefront
These psychedelic stocks are worth accumulating on corrections. The companies are holding clinical trials for mental health drugs.
This small-cap biotech may very well revolutionize how we treat depression.
COMPASS Pathways is a biotech psychedelic medicine development and therapy company that has developed a synthetic formulation of psilocybin, COMP360, for combatting treatment-resistant depress...
Psychedelic stocks are going to surge as the once "hardcore" group of pschedelic drugs gains widespread mainstream medicinal acceptance. The post Find Your Next 10X Winner in the Burgeoning Sh...
The company's fresh look at psychedelic drugs is attracting lots of attention.
The market is in its early stage, and the players in the space could have a lot of room to run.
Oregon just decriminalized the use of the psychedelic compound psilocybin. Could Compass Pathways, which is testing a synthetic form of the drug as a mental health therapy, be on the cusp of s...
Could psilocybin therapy become a hyper-growth market in mental health medicine? It could happen, so consider a position in CMPS stock.
Highlights include $146.6 million IPO, continued progress with phase IIb psilocybin therapy clinical trial, strengthened board and leadership team, and launch of Drug Discovery Center Highligh...
Oregon became the first state in the nation to legalize the therapeutic use of psychedelic mushrooms, raising awareness for this biotech's trailblazing treatment.
London, UK - 9 November 2020
London, UK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- COMPASS Pathways plc to announce third quarter 2020 financial results on 12 November 2020
Voters in Oregon approved a ballot measure that legalizes a treatment this newly public company has in clinical trials.
London, UK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- COMPASS Pathways plc to participate in Berenberg and Evercore investor conferences
NEW YORK, Nov. 2, 2020 /PRNewswire/ -- For decades, psychedelic therapy was only an experimental idea under research by organizations at academic institutions including Johns Hopkins. This cha...
COMPASS Pathways plc to ring Nasdaq Stock Exchange opening bell in celebration of its successful $146.6 million IPO
The trailblazing company studying the use of the psychedelic drug found in magic mushrooms to treat mental health is starting to make waves.
Compass Pathways uses psychoactive treatment for depression — CEO explains
Biotech company Compass Pathways is up more than 100 since its IPO debut. The company aims to treat depression through psychedelic mushrooms and is backed by Peter Thiel.
The following originally appeared on CapitalWatch An increasing number of Americans becoming increasingly anxious or depressed or worse. To wit, there were more than 72,000 fatal overdoses in ...
In mid-September, the true leader of the Shroom Boom -- COMPASS Pathways (NASDAQ:CMPS) -- finally came public via an IPO that was a huge success. The post Thanks to the Shroom Boom, This Small...
NEW YORK, Oct. 7, 2020 /PRNewswire/ -- Depression, anxiety, post-traumatic stress disorder (PTSD), and other mental illnesses have been prevalent in the US for quite some time, but the coronav...
COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary Shares
CMPS stock shot up more than 70% during its first trading. Here is what else investors need to know about the recent Compass Pathways IPO.
Investors are piling into this newly public psychedelic medicine stock.
Shares of Compass Pathways PLC CMPS, +42.91% pointed north out of the gate, as the first trade was 37.6% above the initial public offering price.
Compass Pathways PLC's stock is set to debut Friday, after the U.K.-based mental health care company's upsized initial public offering price at $17 a share, above the expected range of betwee...
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricin...
About CMPS
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation, which is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
| Industry Research and Development in Biotechnology | IPO Date Sep 18, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol CMPS |
Analyst Forecasts
According to 5 analysts, the average rating for CMPS stock is "Strong Buy." The 12-month stock price forecast is 65.00, which is an increase of 34.52% from the latest price.